04 September 2010
Keywords: Boehringer Ingelheim, Priaxon, R&D collaboration, Cancer
Article | 19 January 2010
German independent drug major Boehringer Ingelheim has entered into a worldwide collaboration with fellow Germany-based drug developer Priaxon to research and develop mdm2/p53 inhibitors for the treatment of cancer.
Under the terms of the deal, Boehringer Ingelheim will pay significant up-front and near-term payments to Priaxon including research funding to support further discovery efforts. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscriptions are £60 per month, pay as you go.
Find out more details.